Patients with relapsing MS treated with tolebrutinib vs teriflunomide had a clear reduction in disability accumulation with no difference in relapses.
Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Zacks Investment Research on MSN1d
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS StudySwiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...
A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...
Columnist Ahna Crum spent years trying to go it alone. Now she knows that freedom comes when she's flocking together with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback